UroGen Pharma (FRA:UR8) Beneish M-Score: -0.56 (As of Jun. 27, 2026)


FRA:UR8 UroGen Pharma Ltd FRA:UR8
67 GF Score
Price €29.44
GF Value €17.05
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma Beneish M-Score?

UroGen Pharma FRA:UR8 -3.22% 67 Beneish M-Score is -0.56 as of Jun. 27, 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 67/100 and a GF Value™ of €17.05 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 831 Biotechnology companies, UroGen Pharma ranks worse than 80.75% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.56 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for UroGen Pharma's Beneish M-Score or its related term are showing as below:

FRA:UR8' s Beneish M-Score Range Over the Past 10 Years
Min: -13.08   Med: -1.41   Max: 950.86
Current: -0.56

During the past 11 years, the highest Beneish M-Score of UroGen Pharma was 950.86. The lowest was -13.08. And the median was -1.41.


UroGen Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Beneish M-Score Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.16 -4.21 -2.62 -2.78 -1.76

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.15 -0.71 -2.86 -1.76 -0.56

FRA:UR8 vs OCS, SEPN, AVBP: Beneish M-Score Comparison

For the Biotechnology subindustry, UroGen Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Beneish M-Score falls into.


FRA:UR8
67GF Score
UroGen Pharma Ltd FRA:UR8
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of UroGen Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.861+0.528 * 0.9981+0.404 * 1.4792+0.892 * 1.4178+0.115 * 0.8668
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8703+4.679 * 0.130476-0.327 * 1.4371
=-0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €47.9 Mil.
Revenue was 44.08 + 32.313 + 23.415 + 20.994 = €120.8 Mil.
Gross Profit was 40.499 + 29.504 + 20.622 + 17.917 = €108.5 Mil.
Total Current Assets was €205.4 Mil.
Total Assets was €219.4 Mil.
Property, Plant and Equipment(Net PPE) was €7.4 Mil.
Depreciation, Depletion and Amortization(DDA) was €2.2 Mil.
Selling, General, & Admin. Expense(SGA) was €147.6 Mil.
Total Current Liabilities was €43.8 Mil.
Long-Term Debt & Capital Lease Obligation was €168.8 Mil.
Net Income was -20.392 + -22.515 + -28.412 + -43.298 = €-114.6 Mil.
Non Operating Income was -0.279 + -0.004 + -0.168 + -0.328 = €-0.8 Mil.
Cash Flow from Operations was -39.198 + -32.73 + -36.014 + -34.528 = €-142.5 Mil.
Total Receivables was €18.2 Mil.
Revenue was 18.735 + 23.46 + 22.709 + 20.297 = €85.2 Mil.
Gross Profit was 16.58 + 21.1 + 20.499 + 18.226 = €76.4 Mil.
Total Current Assets was €219.4 Mil.
Total Assets was €229.0 Mil.
Property, Plant and Equipment(Net PPE) was €5.0 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.2 Mil.
Selling, General, & Admin. Expense(SGA) was €119.6 Mil.
Total Current Liabilities was €38.9 Mil.
Long-Term Debt & Capital Lease Obligation was €115.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(47.931 / 120.802) / (18.165 / 85.201)
=0.396773 / 0.213202
=1.861

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(76.405 / 85.201) / (108.542 / 120.802)
=0.896762 / 0.898512
=0.9981

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (205.406 + 7.401) / 219.442) / (1 - (219.389 + 4.976) / 229.047)
=0.030236 / 0.020441
=1.4792

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=120.802 / 85.201
=1.4178

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.236 / (1.236 + 4.976)) / (2.205 / (2.205 + 7.401))
=0.19897 / 0.229544
=0.8668

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(147.613 / 120.802) / (119.631 / 85.201)
=1.221942 / 1.404103
=0.8703

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((168.828 + 43.799) / 219.442) / ((115.578 + 38.85) / 229.047)
=0.968944 / 0.67422
=1.4371

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-114.617 - -0.779 - -142.47) / 219.442
=0.130476

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

UroGen Pharma has a M-score of -0.65 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.56 mean?
UroGen Pharma (FRA:UR8) has a Beneish M-Score of -0.56 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #671 out of 831 companies in the Biotechnology industry, placing it in the top 80.7%.
Is UroGen Pharma's Beneish M-Score too high?
UroGen Pharma's current Beneish M-Score is -0.56. Based on the distribution chart, UroGen Pharma ranks #671 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Beneish M-Score compare to OCS and SEPN?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #671 out of 831 companies for Beneish M-Score. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Beneish M-Score is -0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current Beneish M-Score is -0.56. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Beneish M-Score is -0.56 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Beneish M-Score: -0.56
  • GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score

Get the complete analysis for FRA:UR8

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.44
Price
€17.05
GF Value